Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations

Thrombosis Research

Volumn 136, Issue 4, 2015, Pages 763-768

  Godier, Anne ^a,b   Martin, Anne Céline ^b,c   Leblanc, Isabelle ^d   Mazoyer, Elisabeth ^e   Horellou, Marie Hélène ^f,g   Ibrahim, Firas ^f   Flaujac, Claire ^f   Golmard, Jean Louis ^h   Rosencher, Nadia ^f   Gouin Thibault, Isabelle ^b,f,g  

^a FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^b Fondation Carpentier   (France)

^c University of Paris Descartes   (France)

^d INSTITUT MUTUALISTE MONTSOURIS   (France)

^e AVICENNE HOSPITAL   (France)

^f université Paris Cité   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anti IIa; Anti Xa; Anticoagulant; aPTT; PT; Surgery

Indexed keywords

DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; ANTITHROMBIN;

AGED; ARTICLE; BLEEDING; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; BLOOD CLOTTING; CLINICAL TRIAL; DRUG EFFECTS;

AGED; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; DABIGATRAN; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RIVAROXABAN;

EID: 84941879698     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.08.006     Document Type: Article

References (17)

1. J.D. Douketis, P.B. Berger, A.S. Dunn, A.K. Jaffer, A.C. Spyropoulos, R.C. Becker, and et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 299S 339S
2. J.S. Healey, J. Eikelboom, J. Douketis, L. Wallentin, J. Oldgren, S. Yang, and et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial Circulation 126 2012 343 348
3. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, and et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary Eur. Heart J. 34 2013 2094 2106
4. V. Pengo, L. Crippa, A. Falanga, G. Finazzi, F. Marongiu, G. Palareti, and et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) Thromb. Haemost. 106 2011 868 876
5. P.A. Reilly, T. Lehr, S. Haertter, S.J. Connolly, S. Yusuf, J.W. Eikelboom, and et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) J. Am. Coll. Cardiol. 63 2014 321 328
6. Xarelto® (rivaroxaban) Summary of product characteristics (2008) Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf (Accessed 19 august 2014)
7. I.Y. Gong, and R.B. Kim Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban Can. J. Cardiol. 29 2013 S24 S33
8. J.D. Douketis, A.C. Spyropoulos, F.A. Spencer, M. Mayr, A.K. Jaffer, M.H. Eckman, and et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e326S e350S
9. A.C. Spyropoulos, and J.D. Douketis How I treat anticoagulated patients undergoing an elective procedure or surgery Blood 120 2012 2954 2962
10. P. Sie, C.M. Samama, A. Godier, N. Rosencher, A. Steib, J.V. Llau, and et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis Arch. Cardiovasc. Dis. 104 2011 669 676
11. J.V. Llau, R. Ferrandis, J. Castillo, J. de Andres, C. Gomar, A. Gomez-Luque, and et al. Management of direct action oral anticoagulants in the peri-operative period and invasive techniques Rev. Esp. Anestesiol. Reanim. 59 2012 321 330
12. S.A. Kozek-Langenecker, A. Afshari, P. Albaladejo, C.A. Santullano, E. De Robertis, D.C. Filipescu, and et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology Eur. J. Anaesthesiol. 30 2013 270 382
13. G. Pernod, P. Albaladejo, A. Godier, C.M. Samama, S. Susen, Y. Gruel, and et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013 Arch. Cardiovasc. Dis. 106 2013 382 393
14. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 2011 883 891
15. T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W. Ageno Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis J. Thromb. Haemost. 11 2013 756 760
16. S.J. Francart, E.M. Hawes, A.M. Deal, D.M. Adcock, R. Gosselin, C. Jeanneret, and et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels Thromb. Haemost. 111 2014 1133 1140
17. A. Cuker, D.M. Siegal, M.A. Crowther, and D.A. Garcia Laboratory measurement of the anticoagulant activity of the non-vitamin k oral anticoagulants J. Am. Coll. Cardiol. 64 2014 1128 1139